Up front combination of ALK and MEK inhibition has improved the response in a preclinical model of EML4-ALK NSCLC, and in a patient derived acquired resistance cellular model of EML4-ALK26,27. Here, MAP2K7 is linked to non-small cell lung carcinoma.